4.8 Article

The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNAAng1+Vegf nanoparticles

期刊

BIOMATERIALS
卷 33, 期 30, 页码 7655-7664

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.06.096

关键词

Stent; Nanoparticles; Restenosis; Hydrogel; Endothelium

资金

  1. Natural Sciences and Engineering Research Council of Canada (NSERC)
  2. Canadian Institute of Health Research [MOP 93641]

向作者/读者索取更多资源

This study report the development of a nanobiohybrid hydrogel based endovascular stent device capable of preventing postangioplasty in-stent restenosis (ISR) by promoting significant vascular endothelial recovery in a site-specific manner. The hydrogel is comprised of fibrin matrices, assembled layer-by-layer (LbL) on stent surface with alternate layers carrying endosomolytic Tat peptide/DNA nanoparticles (NPs) or NPs hybridized to polyacrylic acid (PM) wrapped single-walled carbon nanotubes (NP-CNT). Here, the hydrogel works as a reservoir to carry, protect, and simultaneously deliver pro-angiogenic, vascular endothelial growth factor (Vegf) and Angiopoietin-1(Ang1), gene carrying NPs to the target site. In vitro results demonstrated that CNTs incorporated in the hydrogel layers play a major role in tuning the bioactivity of the stent. In addition, the developed stent formulation can significantly reduce the loss of therapeutics while traversing through the vessel and during deployment. In vivo experiments in balloon-injured canine femoral artery demonstrated that the NCS (+) group, carrying NPvegf+Ang1, can significantly enhance re-endothelialization of injured artery compared to control NCS (-), carrying NPNull, and bare metal stent (BMS) groups, attenuate stenosis (18.5 +/- 9.03% vs 39.56 +/- 13.8 vs 45.34 +/- 8.3%; n = 8, p < 0.05) and prevent neointima formation (1.53 +/- 0.36 mm(2) vs 2.51 +/- 0.27 mm(2) vs 2.66 +/- 0.14 mm(2); n = 8, p < 0.05) as analyzed angiography and histomorphometric analysis. These data collectively implicate that this new technology can be useful for stent and other biomedical devices through controlled delivery of multiple biotherapeutics. (C) 2012 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据